The effect of paliperidone palmitate long-acting injectable (PP-LAI) on “non-core” symptoms of schizophrenia: a retrospective, collaborative, multicenter study in the “real world” everyday clinical practice

**Summary.** Background. Schizophrenia is frequently complicated by the occurrence of depressive symptoms, anhedonia, obsessions and compulsions, suicidal ideation, and substance abuse, that causes exacerbations and remissions and, in several cases, sustained morbidity and disability. Aim. The present study aimed to evaluate the effect of paliperidone palmitate once-monthly long-acting injection (PP-LAI) mainly on “non-core” symptoms in persons with recent diagnosis schizophrenia, during a follow-up period of almost 12 months (T1) in the context of the “real world” everyday clinical practice. Results. Concerning core symptoms of schizophrenia, PP-LAI was effective in reducing all symptoms at T1 as measured by Positive and Negative Syndrome Scale (PANSS), including depressive symptoms, and increased the functioning. Moreover, concerning the non-core symptoms of schizophrenia, PP-LAI treatment was effective in reducing scores of anhedonia, suicidal ideation and obsessive-compulsive symptoms at T1. However, the levels of alexithymia remained relatively stable, even if reduced. Discussion. The present retrospective, multicenter, non-sponsored, collaborative study showed that early PP-LAI treatment was effective in improving almost all the core dimensions and “non-core” symptoms of schizophrenia, and this may have positive repercussions on both functioning and quality of life. Conclusions. PP-LAI treatment should be offered earlier as possible and was effective on “non-core” symp-
toms of schizophrenia at follow-up, but had a little effect on alexithymia. However, study limitations must be considered and future researches are needed to confirm these interesting findings.

KEY WORDS: schizophrenia, paliperidone palmitate, depression, functioning, anhedonia, obsessions, compulsions, suicidal ideation, craving, alexithymia, real world.

INTRODUCTION

Schizophrenia is a chronic, severe, and disabling disorder that is characterized by positive, negative, cognitive, and affective symptoms. Schizophrenia is frequently complicated by the occurrence of suicidal ideation and behaviors, violent and aggressive behaviors, substance abuse, and medical comorbidities that can arise over an illness course that causes exacerbations and remissions and, in several cases, sustained morbidity and disability. The pharmacological treatment of schizophrenia is mandatory, as subjects with this disorder have a less life expectancy and higher mortality than the general population, especially if they are not treated. The long-acting antipsychotic injections (LAIs) are considered as an adherence intervention for patients who are ‘non-compliant’ with the oral medication they have been prescribed. However, the availability of the Long-acting injectable second-generation antipsychotics (SGAs-LAIs) has been an advance in the long-term management of schizophrenia, particularly regarding subjective and objective long-term tolerability.

Even if the SGAs-LAIs are usually used to maintain treatment adherence in patients with chronic schizophrenia, recent studies suggest that they may also provide an effective treatment strategy for persons with first-episode schizophrenia. Moreover, these drugs may also have a potential "neuroprotective" effect, thus improving the neurodegenerative outcomes of psychosis. This effect may also be explained and is reinforced by the better quality of life that is often obtained in persons treated with the SGAs-LAIs. However, even if the research on SGAs-LAIs effects on core symptoms of schizophrenia (i.e., positive and negative symptoms, disorganization, diminished emotional expression, and cognitive symptoms) is continuously growing, there are few data on the effects of such drugs on non-core symptoms of schizophrenia that often are present even when the core symptoms are improved. Frequently, it has been observed the emergence of depressive symptoms, suicidal ideation, anhedonia, obsessive-compulsive symptoms, alexithymia, and substance craving in schizophrenia, even if the core symptoms have been adequately treated.

Paliperidone palmitate once-monthly long-acting injection (PP-LAI) has been approved for the treatment of schizophrenia by the Food and Drug Administration in 2009 and by the European Medicines Agency in 2011. PP-LAI is hydrolyzed to paliperidone, the primary active metabolite of risperidone. The PP-LAI mechanism of action is a combination of central dopamine D2 and serotonin 5HT2A receptor antagonism. As well, PP-LAI showed an antagonism for α1 and α2-adrenergic receptors and, to a lesser extent, for H1 histaminergic receptors, without affinities for cholinergic or muscarinic receptors.

Currently, there are not specific studies that have investigated the action of SGAs-LAIs in all these “non-core” symptoms clusters. Therefore, the present study aimed to evaluate the effect of PP-LAI mainly on “non-core” symptoms in persons with recent diagnosis schizophrenia during a follow-up period of almost 12 months in the context of the “real world” everyday clinical practice.

METHODS

This multicentric, retrospective, and observational study, not funded or sponsored, was conducted in several mental health facilities in Central and South Italy among patients with recent diagnosis schizophrenia who were initiated with PP-LAI, based on an attending physician’s clinical judgment and patient agreement. Patients with five or fewer years of illness affected by schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), were evaluated and included in the analysis. Patients were allowed to continue on any prescribed anxiolytics or mood stabilizers (valproate), if any, during the trial. Patients who were taking other antipsychotics or...
The effect of paliperidone palmitate long-acting injectable (PP-LAI) on “non-core” symptoms of schizophrenia

Concerning core symptoms of schizophrenia, PP-LAI was effective in reducing both positive and negative symptoms at T1 as measured by PANSS (respectively t=11.6 df 69 p<0.001 and t=8.7 df 69 p<0.001). As well, also DIS (t=11.4 df 69 p<0.001), EXC (t=5.2 df 69 p<0.001) and DEP (t=6.9 df 69 p<0.001) factors of PANSS improved with PP-LAI treatment at 12 months. Also functioning (as measured by GAF; t=-7.8 df 69 p<0.001) improved with the PP-LAI (Figure 1).

Concerning the non-core symptoms of schizophrenia, PP-LAI treatment was effective in reducing scores of anhedonia (as measured by SHAPS, t=6.5 df 69 p<0.001), suicidal ideation (as measured by SSI, t=5.9 df 69 p<0.001) and obsessive-compulsive symptoms (as measured by Y-BOCS total score, t=8.7 df 69 p<0.001) at T1. However, the overall rating on TAS-20 remained relatively stable and wasn’t substantially influenced by the PP-LAI administration (Figure 2).

RESULTS

The mean dosage of PP-LAI at the endpoint was 86.4±20.1 mg and the majority of individuals received a dosage of 75 mg/once monthly at T1 (n=40, 57.1%). The mean duration of illness was 3.7±1.2 years, and the mean age at onset was 21.3±2.7 years.

other psychotropic drugs were not considered for enrollment. The persons’ charts were collected and reviewed, and data were obtained at baseline (T0) and prospectively followed up to 12 months (T1).

Persons were excluded based on the following criteria: 1) current or past comorbid diagnosis of autistic disorder or other pervasive developmental disorder; 2) history of severe head injury; 3) harsh medical conditions or significant neurological disorders, including mental retardation and dementia; and 4) any current other psychiatric diagnoses rather than schizophrenia. The use of cannabis wasn’t considered an exclusion criterion because of the high prevalence of its use among schizophrenia patients.

Seventy subjects (41 males and 29 females with a mean age of 25.1±2.6 years) were evaluated, and data analyzed at T0 and T1. Data on sociodemographic and psychopathological variables were collected at the first clinical interview. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS)\(^1\) and, as made by Corigliano et al.,\(^2\) we used the PANSS to extract the following five factors: a) positive (POS) (P1, delusions; P3, hallucinatory behavior; P5, grandiosity; and G9, unusual thought content); b) negative (NEG) (N1, blunted affect; N2, emotional withdrawal; N3, poor rapport; N4, passive withdrawal; N6, lack of spontaneity; and G7, motor retardation); c) disorganized/concrete (DIS) (N5, difficulty in abstract thinking; P2, conceptual disorganization; and G11, poor attention); d) excited (EXC) (P4, excitement; P7, hostility; G8, uncooperativeness; and G14, poor impulse control); depressed (DEP) (G2, anxiety; G3, guilt feelings; and G6, depression). Global functioning was assessed with the Global Assessment of Functioning (GAF) Scale\(^3\). All these measures were considered as an evaluation of the core symptoms of schizophrenia.

To assess the non-core symptoms of schizophrenia, the following scales were used. The suicide risk was assessed with the Scale for Suicide Ideation (SSI)\(^4\). The presence of obsessive-compulsive symptoms was assessed with the total score of the Yale-Brown Obsessive-Compulsive Scale (YBOCS)\(^5\). The anhedonia was measured with the Snaith-Hamilton Pleasure Scale (SHAPS)\(^6\). The presence of alexithymia was evaluated, considering the total score of the Italian version of the 20-items Toronto Alexithymia Scale (TAS-20)\(^7\). Finally, to assess the intensity of craving, we used VAScrav, a 10-cm ruler or straight line with one extreme (0) meaning no craving and the other (10) extremely intense craving, allowing a continuous, non-discrete rating of the extent of craving, differently from Likert-type scales\(^8\).

Statistics

We first used the Kolgomorov-Smirnov normality test to test for the normality of distribution of our data. Since data distribution was found to be normal, we proceeded with parametric testing. Student’s t-tests were conducted to assess changes in psychopathological variables from baseline (T0) to follow-up (T1). For all analyses, a conservative significance threshold of p<0.001 was used. All analyses were conducted with the statistical package SPSS (version 17.0.2).
During the entire study period, there were few side effects reported. PP-LAI was well tolerated, and eight subjects (11.4%) reported a slight increase in prolactin levels (all successfully managed with dosage reduction), seven subjects (10%) reported mild subjective sedation and 15 subjects (21.4%) reported a slight pain on the site injection (in almost one administration). No other adverse effects were observed.

DISCUSSION

The present retrospective, multicenter, non-sponsored, collaborative study showed that PP-LAI was effective in improving the positive/negative dimensions, the disorganized and excited dimensions, and the depressive symptoms at 12 months of follow-up. Overall, these findings were in accordance with most of the literature demonstrating the effectiveness of such drug in these dimensions of schizophrenia.21,25. Moreover, offering an LAI antipsychotic is always an effective strategy, especially in early-episode patients, resulting in the administration of treatments when schizophrenia is most treatable.20,33. Brown et al.32 have demonstrated that PP-LAI showed symptomatic and functional improvement in patients with different durations of schizophrenia. Still, the magnitude of the effects was superior in subjects with early illness than in those with a chronic disease. Though it should be noted that we observed a remarkable action on affective symptoms such as depression, and this finding may explain the improvement seen in terms of functioning.35. Moreover, PP-LAI significantly improved the anhedonia. This finding may be related to the reduction in negative/depressive symptoms or the improvement in global functioning (or both)31. Still, it can be hypothesized a peculiar action on PP-LAI on anhedonia itself34, but further studies are needed. The subjects affected by schizophrenia may have functional impairment in anticipatory, but not consummatory reward, anticipating lower pleasure from future activities than healthy controls, and resulting in a decrease in goal-directed behaviors.35. PP-LAI, through the effects on serotonin 5HT2a and 2-adrenergic receptors, may restore the dysfunction of dopamine neurotransmission in reward circuitry, thus improving anhedonia.36

Moreover, PP-LAI treatment was effective in reducing scores of obsessive-compulsive symptoms (even if Y-BOCS total scores were relatively low at the baseline). Obsessive-compulsive disorder (OCD) is often associated with schizophrenia and may represent a significant challenge in the treatment.17,37. The percentage of comorbidity between OCD and schizophrenia varies from 7 and 26%, and it has been suggested the existence of a new clinical entity called ‘schizo-obsessive disorder’ subtype of psychosis that may often be treatment-resistant46,39. In fact, to date, few studies have examined the effect of oral paliperidone in OCD, suggesting that oral paliperidone augmentation is well tolerated and has potential efficacy in the short-term treatment of some patients with SRI-resistant OCD40,41. In the present study, PP-LAI treatment demonstrated a beneficial action on both obsessions and compulsions, and this was the first study that evaluated this long-acting formulation in 70 subjects.42

Another remarkable finding of our study was the observed reduction in suicide ideation with PP-LAI treatment. Suicide is a significant cause of death amid subjects affected by schizophrenia43. The deaths by suicide have been reported in approximately 5% of subjects affected by schizophrenia though this rate appears to underestimate the phenomenon.44. One of the suicide risk factors is represented by poor treatment adherence, and the introduction of a long-acting medication may be a good option in this case45,46. Moreover, rehospitalizations during antipsychotic treatment may be correlated with higher suicide risk.47,48. Tiihonen et al.49 found that available LAI-APs treatments led to a reduction in hospitalizations with PP-LAI superior to other treatments. As well, ensuring a continuous treatment may protect the brain constraining the gray matter loss that is related to schizophrenia and its relapses, and this may also explain the better functioning, the overall good quality of life and the lower suicide risk associated with second generation LAI-APs.50

The craving for substances was significantly reduced by PP-LAI as measured with VASCrav. Substance use disorders (SUDs) are relatively common in subjects affected by schizophrenia. A recent meta-analysis showed that the occurrence of any SUD amid subjects affected by schizophrenia or first-episode psychosis was 42%, with the most common SUDs being those related to illegal drugs (28%), cannabis (21%), alcohol (24%) and psychostimulants (7%)51. The use of LAIs has been demonstrated to be effective in reducing SUDs especially when administered at the first episode52. Substance use is always associated with poor outcomes in schizophrenia, in part because of its negative impact on adherence53 and in part because the neurotoxicity of the substances54. To date, this was the first report that analyzed the effect of PP-LAI on substance craving and the results were similar to those reported for aripiprazole long-acting55. The adherence and the potential neuroprotective effects of PP-LAI and other second generation LAIs may explain this effect. Moreover, the observed positive effects of PP-LAI on core features, depressive symptoms, anhedonia, global functioning and rumination may have also contributed to the craving attenuation and relief.

On the other hand, the total score on TAS-20, even reduced by PP-LAI administration, remained relatively stable and was not significantly influenced by the treatment, suggesting that alexithymia may be considered an independent variable not related to negative symptoms56. This is in accordance with previous studied that pointed out the alexithymia is a relatively stable personality trait that isn’t addressed by medications57. However, as a reduction is TAS-20 total score was observed, we argue that alexithymia would be also a state-dependent phenomenon that increases with higher perceived stress and more prominent symptoms58,59. The state-dependent alexithymia may be relieved by PP-LAI treatment and this may further explain the positive effects on non-core symptoms of schizophrenia, as alexithymia is often associated with more severe depressive symptoms and anhedonia, rumination, and higher suicide risk and SUDs59,60.

Even if the findings of the present study were interesting, the limitations must be considered. The most significant limitation of this study is the possibility of treatment selection biases as the treatment groups were not randomized or consecutive and were carefully selected, which are often the intrinsic flaws of any naturalistic, “real world” studies. Moreover, in the absence of randomization and in presence of a selection bias, one cannot completely exclude the influence of unknown con-
The effect of paliperidone palmitate long-acting injectable (PP-LAI) on “non-core” symptoms of schizophrenia

founders. A possible confounder lies in psychosocial interventions; although the same services were equally offered to every participant, they were not specifically quantified or analysed in this study. Furthermore, the present study did not assess the total number of relapse or hospitalization events over the entire observation period. Finally, other limitations of the present study include the small sample size and the retrospective design using secondary data.

CONCLUSIONS

The present retrospective, multicenter, non-sponsored, collaborative study showed that the early administration of PP-LAI was effective in improving the positive/negative dimensions, the disorganized and excited dimensions, depressive symptoms and the global functioning at 12 months of follow-up.

Moreover, the action of PP-LAI treatment was remarkable also on “non-core” symptoms of schizophrenia at follow-up. PP-LAI treatment was effective in reducing levels of anhedonia, obsessive-compulsive symptoms, suicide ideation and substance craving, but had a little effect on alexithymia. Even if the study’ limitations must be considered, the results are encouraging and strengthen the hypothesis that second generation LAIs should be offered and introduced as early as possible to obtain a better effect on all schizophrenia dimensions and associated symptoms.

Funding source statement and conflicts of interest: all authors under-score that this paper was not funded by any research grants, and no pharmaceutical companies were informed of or involved in. The Authors have no conflicts of interest to declare.

REFERENCES


